ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 12 of 49
УЖМБС 2019, 4(4): 77–83
Clinical Medicine

Investigation of Influence of Chronic Epstein - Barr Virus Infection on the Level of Mir-146A and Mir-155 Expression in Patients with Allergopathy

Zubchenko S. O.1, Maruniak S. O.2, Lomikovska M. P.1

Epstein-Barr (EBV) has the ability of long-life persistence in the human body; it exists in latent form in immunocompetent cells and can be reactivated under the influence of different exo- and endogenous unfavorable factors. Specific tropism of the virus to immunocompetent cells can influence their expression level of microRNA, which are active regulators of immune response. The purpose of the study was to conduct a comparative assessment of miR-146A and miR-155 expression level. Material and methods. The comparative assessment was conducted in two groups of patients with allergopathy in combination with active (1st group) and latent (2nd group) phases of chronic Epstein-Barr virus infection and control group of healthy individuals. Patients underwent clinical, general laboratory, instrumental, specific allergic, molecular genetic studies, cytological examination of the smear from the nasal mucosa. Skin tests were performed with allergen extracts (Diater, Spain). An assessment of the functional state of the lungs was performed on the basis of spinography (Vitalograph ALPHA No. AL011734, Germany). Clinical diagnosis of AR and / or BA was based on the criteria of ARIA (2016), GINA (2016-2017). To determine the general and specific IgE (sIgE) to EBV (EBNA-IgG, EBV-VCA-IgG) antigens and specific antibodies, we used an immunoassay with the Euroimmun test system, Germany, according to the manufacturer's instructions. Determination of DNA of Epstein-Barr virus infection in blood, saliva and mucous membrane of the pharynx was performed the polymeric chain reaction method on AmpliSens diagnostic sets using Rotor Genе 6000 (Corbett Recearch, Australia). Results and discussion. The study results showed that in latent phase, Epstein-Barr virus infection used own mechanisms of latency to avoid immune response, which was characterized by increased synthesis of miR-155 and miR-146A compared with control group. However, the opposite vector of changes of these microRNAs with antagonistic properties was observed compared with active phase. In active phase of Epstein-Barr virus infection, this direction of changes only intensified and was associated with acute manifestations of allergopathy. Patients in the 2nd group also showed higher levels of miR-155, although without a significant difference with the control group, while patients in the 2nd group were characterized by a history of pollen allergy with a history of broncho-obstruction syndrome, blood eosinophilia and nasocytogram. In our opinion, the imbalance between miR-155 and miR-146a, which Epstein-Barr virus infection created to provide a phase of lation, contributed to the chronicity of the allergic inflammatory process. Our conclusion confirmed the data of Okoye and colleagues about the antagonistic role of miR-155 and miR-146a in the regulation of the immune response administered by Th2. Conclusions. The chronic Epstein-Barr virus infection in patients with allergopathy had different influence on miR-155 and miR-146A levels depending on the phase of virus persistence. The increase in the expression of miR-155 initiated an inadequate antiviral response from the side of both humoral and cellular immunity, enhanced cell-mediated inflammation, working unison with miR-146a.

Keywords: Epstein-Barr virus, allergic diseases, miR-155, miR-146A

Full text: PDF (Ukr) 306K

  1. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. The Journal of experimental medicine. 2011; 208(6): 1189-201.
  2. Callegari S, Gastaldello S, Faridani OR, Masucci MG. Epstein–barr virus encoded microRNAs target sumo-regulated cellular functions. FEBS J. 2014; 281: 4935–50.
  3. Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 2013; 38(4): 742–53.
  4. Esau D. Viral Causes of Lymphoma: The History of Epstein-Barr Virus and Human T-Lymphotropic Virus 1. Virology: research and treatment. 2017; 8: 1178122X17731772.
  5. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, et al. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nature immunology. 2013; 14(6): 593–602.
  6. Grinde B. Herpesviruses: latency and reactivation - viral strategies and host response. Journal of oral microbiology. 2013; 5.
  7. Labbaye C, Testa U. The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. Journal of hematology and oncology. 2012; 5: 13.
  8. Liu WH, Kang SG, Huang Z, Wu CJ, Jin HY, Maine CJ, et al. A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. J Exp Med. 2016; 213: 1901–19.
  9. Malmhäll C, Alawieh S, Lu Y, Sjostrand M, Bossios A, Eldh M, et al. MicroRNA-155 is essential for Th2-mediated allergen-induced eosiniphiliuc inflammation in the lung. J Allergy Clin Immunol. 2014; 133: 1429–38.
  10. Mashima R. Physiological roles of miR-155. Immunology. 2015; 145(3): 323–33.
  11. Motsch N, Pfuhl T, Mrazek J, Barth S, Grässer FA. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol. 2007; 4(3): 131–7.
  12. Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA. EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. The EMBO journal. 2012; 31(9): 2207-21.
  13. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007; 316(5824): 608–11.
  14. O’Connell R, Kahn D, Gibson W, Round T, Schole R, Chaudhuri A, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010; 33: 607–19.
  15. Okada H, Kohanbash G, Lotze MT. MicroRNAs in immune regulation--opportunities for cancer immunotherapy. The international journal of biochemistry and cell biology. 2010; 42(8): 1256-61.
  16. Okoye IS, Czieso S, Ktistaki E, Roderick K, Coomes SM, Pelly VS, et al. Transcriptomics identified a critical role for Th2 cell-intrinsic miR-155 in mediating allergy and antihelminth immunity. Proc. Natl. Acad. Sci. USA. 2014; 111: E3081–E3090.
  17. Paladini L, Fabris L, Bottai G, Raschioni C, Calin, GA, Santarpia L. Targeting microRNAs as key modulators of tumor immune response. Journal of experimental and clinical cancer research: CR. 2016; 35: 103.
  18. Wang S, Zhang X, Ju Y, Zhao B, Yan X, Hu J, et al. MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B. J Immunol. 2013; 191(1): 293–301.
  19. Zech A, Ayata CK, Pankratz F, Meyer A, Baudiss K, Cicko S, et al. MicroRNA-155 modulates P2R signaling and Th2 priming of dendritic cells during allergic airway inflammation in mice. Allergy. 2015; 70(9): 1121–29.
  20. Zubchenko SO, Maruniak SR. Effects of herpesvirus infections on formation of allergy pathology. East European Scientific Journal. 2016; 1(10): 15-20.